NASDAQ:ZGNXZogenix Competitors & Alternatives

Johnson & Johnson (NYSE:JNJ) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Johnson & Johnson and Zogenix, as provided by MarketBeat.

Johnson & Johnson presently has a consensus price target of $163.8571, suggesting a potential upside of 14.37%. Zogenix has a consensus price target of $56.80, suggesting a potential upside of 105.95%. Given Zogenix's stronger consensus rating and higher probable upside, analysts plainly believe Zogenix is more favorable than Johnson & Johnson.

Institutional & Insider Ownership

68.5% of Johnson & Johnson shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 3.5% of Zogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Johnson & Johnson has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Johnson & Johnson and Zogenix's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Johnson & Johnson and Zogenix's gross revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Summary

Johnson & Johnson beats Zogenix on 9 of the 14 factors compared between the two stocks.

Zogenix (NASDAQ:ZGNX) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Zogenix and Merck & Co., Inc., as provided by MarketBeat.com.

Zogenix presently has a consensus target price of $56.80, suggesting a potential upside of 105.95%. Merck & Co., Inc. has a consensus target price of $94.1538, suggesting a potential upside of 20.83%. Given Zogenix's higher probable upside, equities analysts clearly believe Zogenix is more favorable than Merck & Co., Inc..

Institutional and Insider Ownership

74.3% of Merck & Co., Inc. shares are owned by institutional investors. 3.5% of Zogenix shares are owned by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Zogenix has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Profitability

This table compares Zogenix and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Zogenix and Merck & Co., Inc.'s gross revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Summary

Merck & Co., Inc. beats Zogenix on 10 of the 14 factors compared between the two stocks.

Zogenix (NASDAQ:ZGNX) and Pfizer (NYSE:PFE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Zogenix and Pfizer's revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zogenix and Pfizer's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for Zogenix and Pfizer, as reported by MarketBeat.

Zogenix currently has a consensus target price of $56.80, suggesting a potential upside of 105.95%. Pfizer has a consensus target price of $38.6083, suggesting a potential upside of 14.40%. Given Zogenix's stronger consensus rating and higher probable upside, research analysts plainly believe Zogenix is more favorable than Pfizer.

Risk & Volatility

Zogenix has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Institutional and Insider Ownership

70.3% of Pfizer shares are owned by institutional investors. 3.5% of Zogenix shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Pfizer beats Zogenix on 8 of the 14 factors compared between the two stocks.

Zogenix (NASDAQ:ZGNX) and Eli Lilly And Co (NYSE:LLY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Zogenix and Eli Lilly And Co's revenue, earnings per share (EPS) and valuation.

Eli Lilly And Co has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zogenix and Eli Lilly And Co's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for Zogenix and Eli Lilly And Co, as reported by MarketBeat.

Zogenix currently has a consensus target price of $56.80, suggesting a potential upside of 105.95%. Eli Lilly And Co has a consensus target price of $169.7273, suggesting a potential upside of 0.35%. Given Zogenix's stronger consensus rating and higher probable upside, research analysts plainly believe Zogenix is more favorable than Eli Lilly And Co.

Risk & Volatility

Zogenix has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Eli Lilly And Co has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Institutional and Insider Ownership

77.4% of Eli Lilly And Co shares are owned by institutional investors. 3.5% of Zogenix shares are owned by insiders. Comparatively, 0.1% of Eli Lilly And Co shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Eli Lilly And Co beats Zogenix on 9 of the 15 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Profitability

This table compares AbbVie and Zogenix's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for AbbVie and Zogenix, as reported by MarketBeat.com.

AbbVie currently has a consensus price target of $106.80, suggesting a potential upside of 7.57%. Zogenix has a consensus price target of $56.80, suggesting a potential upside of 105.95%. Given Zogenix's higher probable upside, analysts plainly believe Zogenix is more favorable than AbbVie.

Valuation & Earnings

This table compares AbbVie and Zogenix's revenue, earnings per share and valuation.

AbbVie has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

72.4% of AbbVie shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 3.5% of Zogenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

AbbVie has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Summary

AbbVie beats Zogenix on 9 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares Bristol-Myers Squibb and Zogenix's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Bristol-Myers Squibb and Zogenix, as reported by MarketBeat.

Bristol-Myers Squibb presently has a consensus price target of $68.1667, suggesting a potential upside of 14.45%. Zogenix has a consensus price target of $56.80, suggesting a potential upside of 105.95%. Given Zogenix's stronger consensus rating and higher possible upside, analysts clearly believe Zogenix is more favorable than Bristol-Myers Squibb.

Valuation and Earnings

This table compares Bristol-Myers Squibb and Zogenix's revenue, earnings per share and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

74.2% of Bristol-Myers Squibb shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 3.5% of Zogenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Bristol-Myers Squibb has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats Zogenix on 9 of the 14 factors compared between the two stocks.